Limits...
A survey on the distribution of healthy people with different anti-tumour ability.

Gao Y, Xu X, Dong Z, Jiang C, Gao J, Hu J, Gui J, Wang H, Tian Y - Arch Med Sci (2010)

Bottom Line: The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells.We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells.From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, China.

ABSTRACT

Introduction: The aim of the study was to explore the distribution of healthy people with different anti-tumour ability.

Material and methods: Leukocytes were separated by the Ficoll-Hypaque density gradient centrifugal method. Then they were mixed with A549, MCF-7 and Hela cells at different ratios. The survival rate for target cells was observed and counted by Fluoroskan. Immune function for 200 healthy people was analysed by flow cytometry.

Results: The results obtained by confocal microscopy revealed that human blood leukocytes possessed direct anti-tumour activity. The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells. We speculated that in 200 healthy people the leukocyte capacity for killing MCF-7 cells is stronger than the leukocyte capacity for killing A549 cells and Hela cells. We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells. The number of healthy people with the strongest anti-tumour ability was highest when the target cells were MCF-7 cells. Moreover, the survival of A549, MCF-7 and Hela cells was correlated with T, B and NK lymphocytes.

Conclusions: From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.

No MeSH data available.


Related in: MedlinePlus

Survival rate for Hela cells. After separating 200 blood donors’ leukocytes with the Ficoll-Hypaque density gradient method, tumour cells labelled with CFSE were mixed with leukocytes at different ratios and incubated for 48 h at 37°C. The images were obtained with confocal microscopy (Fluoroskan). (A) Hela cells labelled with CFSE; (B) The ratio of effector cells to Hela cells was 5 : 1; (C) The ratio of effector cells to Hela cells was 10 : 1; (D) The ratio of effector cells to Hela cells was 20 : 1. Scale bars: 50 µm
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298353&req=5

Figure 3: Survival rate for Hela cells. After separating 200 blood donors’ leukocytes with the Ficoll-Hypaque density gradient method, tumour cells labelled with CFSE were mixed with leukocytes at different ratios and incubated for 48 h at 37°C. The images were obtained with confocal microscopy (Fluoroskan). (A) Hela cells labelled with CFSE; (B) The ratio of effector cells to Hela cells was 5 : 1; (C) The ratio of effector cells to Hela cells was 10 : 1; (D) The ratio of effector cells to Hela cells was 20 : 1. Scale bars: 50 µm


A survey on the distribution of healthy people with different anti-tumour ability.

Gao Y, Xu X, Dong Z, Jiang C, Gao J, Hu J, Gui J, Wang H, Tian Y - Arch Med Sci (2010)

Survival rate for Hela cells. After separating 200 blood donors’ leukocytes with the Ficoll-Hypaque density gradient method, tumour cells labelled with CFSE were mixed with leukocytes at different ratios and incubated for 48 h at 37°C. The images were obtained with confocal microscopy (Fluoroskan). (A) Hela cells labelled with CFSE; (B) The ratio of effector cells to Hela cells was 5 : 1; (C) The ratio of effector cells to Hela cells was 10 : 1; (D) The ratio of effector cells to Hela cells was 20 : 1. Scale bars: 50 µm
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298353&req=5

Figure 3: Survival rate for Hela cells. After separating 200 blood donors’ leukocytes with the Ficoll-Hypaque density gradient method, tumour cells labelled with CFSE were mixed with leukocytes at different ratios and incubated for 48 h at 37°C. The images were obtained with confocal microscopy (Fluoroskan). (A) Hela cells labelled with CFSE; (B) The ratio of effector cells to Hela cells was 5 : 1; (C) The ratio of effector cells to Hela cells was 10 : 1; (D) The ratio of effector cells to Hela cells was 20 : 1. Scale bars: 50 µm
Bottom Line: The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells.We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells.From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, China.

ABSTRACT

Introduction: The aim of the study was to explore the distribution of healthy people with different anti-tumour ability.

Material and methods: Leukocytes were separated by the Ficoll-Hypaque density gradient centrifugal method. Then they were mixed with A549, MCF-7 and Hela cells at different ratios. The survival rate for target cells was observed and counted by Fluoroskan. Immune function for 200 healthy people was analysed by flow cytometry.

Results: The results obtained by confocal microscopy revealed that human blood leukocytes possessed direct anti-tumour activity. The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells. We speculated that in 200 healthy people the leukocyte capacity for killing MCF-7 cells is stronger than the leukocyte capacity for killing A549 cells and Hela cells. We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells. The number of healthy people with the strongest anti-tumour ability was highest when the target cells were MCF-7 cells. Moreover, the survival of A549, MCF-7 and Hela cells was correlated with T, B and NK lymphocytes.

Conclusions: From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.

No MeSH data available.


Related in: MedlinePlus